Scholar Rock Apitegromab + Tirzepatide EMBRAZE Phase 2: 54.9% Lean Mass Preservation Continues to Set Muscle-Sparing Bar
Scholar Rock's apitegromab — a selective pro/latent myostatin antibody approved for SMA — continues to draw obesity-pipeline attention with EMBRAZE Phase 2 data showing 54.9% relative lean mass preservation when combined with tirzepatide vs tirzepatide alone (4.2 lbs / 1.9 kg additional lean mass preserved, p=0.001). Body composition shifted from 70% fat/30% lean with tirzepatide alone to 85%/15% with the combination. SRK-439 next-gen selective myostatin inhibitor is in preclinical development with attenuation of fat-mass rebound after GLP-1 withdrawal as a key signal.